Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation
Similarity between 40 mg b.i.d. and 80 mg q.d. regimens was investigated, demonstrating similar and substantial efficacy with well-tolerated safety in patients without T315I mutation. The 200-mg b.i.d. dose was deemed safe and effective for patients with T315I mutation.
Authors
- Sherwin K. B. Sy (ORCID: https://orcid.org/0000-0001-6405-9130)
- S. S. Kapoor (ORCID: https://orcid.org/0000-0003-4216-8488)
- François Pierre Combes (ORCID: https://orcid.org/0000-0002-8637-7372)
- Yu‐Yun Ho
- Kohinoor Dasgupta
- Matthias Hoch (ORCID: https://orcid.org/0009-0005-1033-2716)
- Sebastien Lorenzo
- Ying Fei Li (ORCID: https://orcid.org/0000-0002-1406-8538)
Institutions
- Novartis (Switzerland) (CH)
- Novartis (India) (IN)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1007/s40262-024-01411-1
- Citations
- 8
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.64
Funders
- Novartis Pharmaceuticals Corporation